Company profile: TransCure BioServices
1.1 - Company Overview
Company description
- Provider of predictive preclinical R&D services via fee-for-service access to humanized mouse platforms, including CD34+ humanized immune system, humanized liver, immuno-oncology, IBD, inflammatory disorder, and infectious disease (HIV, HBV) models, used to profile new drugs and assess efficacy/toxicity, drug-drug interactions, immunotherapies, and antivirals.
Products and services
- CD34+ Humanized Mouse Models: Preclinical-grade mouse assemblies engineered by transplanting CD34+ hematopoietic stem cells to reconstitute a human immune system for studying cancer, inflammatory, autoimmune diseases and profiling new drugs
- Infectious Disease Mouse Models: Translational component platforms for HIV and HBV that emulate infection dynamics to evaluate antiviral therapeutics and prevention strategies in controlled preclinical studies
- Immuno-Oncology Models: Custom-engineered mouse systems that mimic human tumor–immune interactions to interrogate tumor development and rigorously assess immunotherapies in preclinical R&D
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to TransCure BioServices
Natural Pharmaceuticals
HQ: Poland
Website
- Description: Provider of science- and technology-driven health offerings focused on the Omega-3 segment; a Norwegian market leader dedicated to raising awareness among Central European consumers of the health benefits of diets rich in fish and marine fatty acids.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Natural Pharmaceuticals company profile →
CordenPharma
HQ: Switzerland
Website
- Description: Provider of contract development and manufacturing services to pharmaceutical and biotechnology companies, including APIs with development, scale-up and regulatory support; non-sterile and sterile drug products (oral solids, liquids, lyophilized); synthetic lipid excipients (standard and custom); peptide development and manufacturing; and support for bioavailability, LNP formulation/manufacturing, and packaging.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CordenPharma company profile →
NJ Bio
HQ: United States
Website
- Description: Provider of integrated chemistry and biology CRO/CDMO services for biotech and pharma, including bioconjugation and antibody-drug conjugates, protein production, and cell-based assays. Offerings include express, standard, and custom conjugations for ADC assessment and validation, protein/peptide drug conjugates, and carrier protein conjugates for vaccines and antibody generation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NJ Bio company profile →
Navitas Life Sciences
HQ: United States
Website
- Description: Provider of services for Finbrin Split products and data science and supply chain solutions for large pharma, leveraging expert teams from TAKE Life Sciences and WCI Consulting and specialists in clinical development, regulatory, technology, and consulting to deliver client insights.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Navitas Life Sciences company profile →
Presidio Medical
HQ: United States
Website
- Description: Provider of a transformational neuromodulation platform and ULF Neuromodulation Therapy, which uses ultra low frequency current waveforms to inhibit pain signals; shown effective in clinical trials for chronic pain without causing paresthesia, enabling remedies for disorders affecting neuronal activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Presidio Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for TransCure BioServices
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to TransCure BioServices
2.2 - Growth funds investing in similar companies to TransCure BioServices
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for TransCure BioServices
4.2 - Public trading comparable groups for TransCure BioServices
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →